Aevi Genomic Medicine (Aevi Genomic Medicine) Shares Outstanding (Basic Average) : 64.77 Mil (As of Sep. 2019)

Aevi Genomic Medicine Shares Outstanding (Basic Average) Chart

Aevi Genomic Medicine Annual Data
	Trend	Dec09	Dec10	Dec11	Dec12	Dec13	Dec14	Dec15	Dec16	Dec17	Dec18
Shares Outstanding (Basic Average)		Get a 7-Day Free Trial					19.25	26.78	35.16	41.68	61.38

Aevi Genomic Medicine Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
Shares Outstanding (Basic Average)	Get a 7-Day Free Trial															62.02	64.80	64.77	64.77	64.77

Aevi Genomic Medicine Shares Outstanding (Basic Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

Aevi Genomic Medicine  (NAS:GNMX) Shares Outstanding (Basic Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.

Aevi Genomic Medicine Shares Outstanding (Basic Average) Related Terms

Thank you for viewing the detailed overview of Aevi Genomic Medicine's Shares Outstanding (Basic Average) provided by GuruFocus.com. Please click on the following links to see related term pages.

Aevi Genomic Medicine (Aevi Genomic Medicine) Business Description